DOCSLIB.ORG

8N8-Industry Watch

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
8N8-Industry Watch Industry Watch Industry Watch • Peplin’s Anti-AK Drug Enters IND Filing p.416 • China’s Anti-fungal Drug Marketp.418 • DRL & UCB over Levetiracetam Patent Dispute p.420 • Elder Pharma Secures Exclusive Cosmoceuticals Marketing Agreement p.421 • Lupin Pharma Collaborates with Allergan to Promote TM Zymar p.422 • Dainippon Pharma’s Latest Strategic 5-Year Management Plan p.423 •PVAC Therapy Development Discontinued p.426 APBN • Vol. 8 • No. 8 • 2004 415 www.asiabiotech.com Australia Industry Watch Peplin’s Anti-AK Drug n the latest development of its research collaboration with the Australian biotechnology I company Peplin Biotech Ltd, Allergan presented key information regarding the topical drug currently developed by Peplin for actinic keratosis (AK) and non- melanoma skin cancer (NMSC). Allergan will be filing an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to initiate a Phase I/II proof of concept clinical trial in disease patients by the second quarter of 2004. As the sponsor of the IND, Allergan will likely be responsible for the product’s clinical development. Peplin has received an upfront payment of US$1 million on signing of its collaboration agreement with Allergan. Expected to receive up to another US$22 million, compromising of milestone payments and development payments, Peplin stands to receive royalty payments on net sales as well. Peplin has already received US$500, 000 as the first quarterly installment of the developmental payments for 2004. The projected IND filing will mark the next milestone under the collaboration agreement signed between the two companies, with further milestones on commencement of phase III clinical trials, NDA filing and NDA approval. About Peplin Biotech Contact Details: Peplin Biotech Based in Brisbane, Australia, Peplin Biotech Ltd. is a biotechnology company focused on the discovery and development of prescription human therapeutic Address: PO Box 346, Fortitude Valley products for the treatment of cancer. Its strategy is to leverage its pipeline of novel Queensland 4006, Australia proprietary products through collaborative development arrangements with Tel: +61 7 3854 0980 international pharmaceutical companies. Peplin’s lead product is a potential topical therapy for actinic keratosis and non-melanoma skin cancer æ the subject of a joint Fax: +61 7 3854 0980 development and license agreement with Allergan, Inc., a company based in Irvine, Email: [email protected] California. URL: www.peplin.com 416 APBN • Vol. 8 • No. 8 • 2004 Enters IND Filing Industry Watch Known as the early symptom of skin cancer, actinic keratosis is a common form of lesion of the outermost layer of the skin (epidermis) caused by long-term exposure to sunlight, particularly exposure to ultraviolet wavelengths. AKs are known to appear mostly in middle- aged patients (between 40 and 50) who have gone through years of chronic exposure to the sun. In regions where the sunlight is especially intense, AKs can be found in persons as young as in their teens or twenties. It is believed that AK affects at least half of the Caucasian population over 40 years of age and an alarming 78% of these patients suffer from multiple lesions. Up to a tenth of AKs would develop into squamous cell carcinoma (SCC) if left untreated. Squamous cell carcinoma is the second most common form of skin cancer after basal cell carcinoma. Occurring on all areas of the body but most common in areas exposed to the sun, squamous cell carcinoma is diagnosed by the appearance of tumors on parts of the body. The disease may also occur where the skin has been afflicted with certain kinds of injury: burns, scars, long- standing sores, exposure to X-rays or certain chemicals (such as arsenic and petroleum by-products). Several different conditions of AK have been identified by doctors as being precursors to the development of squamous cell carcinoma. About Allergan Contact Details: Allergan, Inc. With headquarters in Irvine, California, Allergan, Inc. is a global specialty pharmaceutical company that develops and commercializes Address: PO Box 19534, Irvine, innovative products for the eye care, neuromodulator, skin care and other California 92623, USA specialty markets. In addition to its discovery-to-development research Tel: +1 714 246 4500 programs, Allergan has global marketing and sales capabilities that deliver value to consumers, satisfy unmet medical needs and improve people’s lives. Fax: +1 714 246 4971 Driven by technology and innovation, Allergan addresses the needs of consumers across the world, with over 5,000 employees worldwide, four Research and Development facilities and three state-of-the-art manufacturing plants. APBN • Vol. 8 • No. 8 • 2004 417 www.asiabiotech.com China China’s Industry Watch Anti-fungal Drug Market Table 1. Hospital Consumption. Hospital Consumption Drug Market Share (%) Fluconazole 49.17 1 A survey conducted in 236 hospitals from 14 big cities had Itraconazole 13.49 revealed that hospital consumption amounted to US$1.55 billion Terbinafine 12.39 in 2002, with revenue standing at US$16.26 million. Econazole 6.94 Miconazole Nitrate 5.50 Fluconazole dominated the hospital consumption, capturing Bifonazole 3.09 Ketoconazole 3.09 49.17% of the market share, followed by Itraconazole at 13.49% Ciaclopirox Olamine 1.67 and Terbinafine at 12.39%. (Table 1) in terms of dosage, injection Clotrimazole/benzyl Alcohol 0.92 form is popular among hospitals, occupying 38.14% of the market, Amphotericin B 0.98 Selenium Sulfide 0.81 followed by capsule (24.94%), ointment (21.74%) and tablet Compound Ketoconazole 0.70 (13.20%) (Table 2). Mycospor 0.12 Flucytosine 0.41 By category, Triazole took up 62.97% of the market share while Amorolfine 0.21 Imidazole’s and antibiotics’ shares stood at 18.67% and 2.84%, Ofloxacin 0.05 respectively; the remaining 15.52% were filled by others. As of Clotrimazole 0.07 Miconazole 0.03 2002, Pfizer (Dalian) led the market, holding 32.79% market share, Compound Clotrimazole 0.04 followed by Janssen (Xi’an) at 27.24% and Shandong Qilu at 5.75% Methylrosaniline Chloride 0.02 (Table 3). Kitpat 0.01 Others 0.29 Among the 140 anti-fungal drug producers in China, the 10 Total 100 companies already covered >90% of the whole hospital market in the selected 14 cities. In particular, Diflucan (Pfizer), Daktarin (Jassen), Pevisone (Jassen), Triatop (Jassen), and Sporanox (Jassen) Table 2. Dosage Preference. had successfully occupied 50% of the market. Dosage Forms Market Share (%) Ranked as the No. 1 drug in hospitals, Diflucan by Dalian Injection 38.14 Pfizer accounted for 32.19% of the total hospital consumption, while Xi’an Jassen’s products: Sporanax, Pevisone, Daktarin and Capsule 24.94 Triatop ranked as No. 2, 3, 5 & 8 respectively. Lamisil (Beijing Ointment 21.74 Novartis) ranked No. 6. In a joint-venture orientated market, three Tablet 13.20 domestic products managed to squeeze in the top 10 list, these Injection Powder 1.13 drugs are: Dingke from Shandong Qilu, Sunve Pharmaceutical Co. Suspension 0.81 Ltd. and ciclopirox olamine from Beijing No. 3 Pharmaceutical Gel 0.01 Co. (Table 4). Suppository 0.02 Others 0.01 1 Beijing, Shanghai, Nanjing, Harbin, Tianjin, Guangzhou, Hangzhou, Shenyang, Jinan, Wuhan, Total 100 Changsha, Shijiazhuang, Xi’an, and Zhengzhou. 418 APBN • Vol. 8 • No. 8 • 2004 Industry Watch Table 3. Top 10 Companies by Market Share (2002). Table 4. Major Brands in 2002 Hospital Market. Rank Company Market Share (%) Brand Ingredient Dosage form Market Share (%) 1Dalian Pfizer 32.79 Diflucan Fluconazole Capsule 32.19 2 Xi’an Janssen 27.24 Sporanox Itraconazole Capsule 14.09 3 Shandong Qilu 5.75 Pevisone Econazole Ointment 5.07 4 Beijing Novartis 5.33 Dingke Terbinafine Ointment 5.55 5 Shanghai Sunve 3.24 Daktarin Miconazole Nitrate Ointment 5.41 6 Jiangsu Yangtze River 3.07 Lamisil Tablet Terbinafine Tablet 5.29 7 Shanghai Sine 2.37 Sunvecon Fluconazole Capsule 3.21 Triatop Ketoconazole Solution 2.50 8Hainan Mankexing 2.36 Mycospor Bifonazole Ointment 1.92 9Bayer 2.28 Ciclopirox Ciclopirox Olamine Ointment 1.58 10 Beijing No.6 (Wanhui Pharma) 1.66 Retail Market The reign looks quite different when the retail (from the same company), Lanmeishu cream from market for anti-fungal drug market is concerned. Tianjin SmithKline & French, Lamisil tablet from Xi’an Jassen dominated the markets in three big cities Novartis. æ Beijing, Shanghai and Guangzhou æ with Sporanox outperforms Daktarin in both Daktarin and Sporanax ranked No. 1 and No. 2; ingredient and effect aspects. Given sufficient time, while Pevisone and Triatop performing not bad at it is believed that Sporanox will gain more market all. This has very much to do with the products’ share, threatening Daktarin’s sovereignty. market positioning. Daktarin is targeted at dermatophytosis, Triatop at dandruff, Sporanox for On the other hand, competition between broad anti-fungal spectrum, and Pevisone at Lamisil (Lamisil tablet and Lanmeishu cream) and providing quick itch relief. Other products with Daktarin has been fierce over the OTC market. considerable coverage include Lamisil tablet from Strategies involving aggressive marketing effort Novartis, Lanmeishu cream from Tianjin SmithKline were launched in an attempt to create market & French. awareness. Some local Chinese companies (e.g. Shandong Lukang Pharmaceutical Group) were Daktarin remains the most popular choice quick to duplicate the ingredients and register among consumers living in these cities: Beijing, patent for Lamisil ahead of Novartis while the big Shanghai, Shenyang, Nanjing, Fuzhou, Dandong, players were fighting for more market share. The Huaiyin, Changzhou, Changshu and Haimen. In fact, aggressive launch has been successful and it has been the leading product in the anti-fungal indirectly helped the local companies to save the market for many years. However, its lead soon faces effort and costs in promoting their products.
Load more

Recommended publications
  • New Insights Into the Effect of Amorolfine Nail Lacquer
    Review article New insights into the effect of amorolfine nail lacquer C. Flagothier, C. Pie´ rard-Franchimont and G. E. Pie´ rard Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains uncertain. Several factors account for treatment failure, of which the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The taxonomic nature and ungual location of the fungus cannot be neglected, besides the type of nail and its growth rate. In addition, the biological cycle of the fungus and the metabolic activity of the pathogen likely play a marked influence in drug response. The presence of natural antimicrobial peptides in the nail is also probably a key feature controlling the cure rates. There are many outstanding publications that cover the full spectrum of the field. The purpose of this review is to put in perspective some facets of activity of the topical treatment using amorolfine nail laquer. The antifungal activity of the drug is likely less pronounced in onychomycosis than that expected from conventional in vitro studies. However, the nail laquer formulation should reduce the propensity to form antifungal-resistant spores and limit the risk of reinfection. Key words: amorolfine, antifungal, fungus, onychomycosis, spore. Topical treatments are often considered to be less Introduction efficacious than current oral treatments. However, some During the last 2 decades, the efficacy of treating topical formulations may provide effects that cannot be onychomycoses has been considerably improved by achieved by other treatments. In discussing the treat- the introduction of new generations of potent antifun- ment of onychomycosis, it should not be forgotten that gals.
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Lactoferrin, Chitosan and Melaleuca Alternifolia—Natural Products That
    b r a z i l i a n j o u r n a l o f m i c r o b i o l o g y 4 9 (2 0 1 8) 212–219 ht tp://www.bjmicrobiol.com.br/ Review Lactoferrin, chitosan and Melaleuca alternifolia—natural products that show promise in candidiasis treatment ∗ Lorena de Oliveira Felipe , Willer Ferreira da Silva Júnior, Katialaine Corrêa de Araújo, Daniela Leite Fabrino Universidade Federal de São João del-Rei/Campus Alto Paraopeba, Minas Gerais, MG, Brazil a r t i c l e i n f o a b s t r a c t Article history: The evolution of microorganisms resistant to many medicines has become a major chal- Received 18 August 2016 lenge for the scientific community around the world. Motivated by the gravity of such a Accepted 26 May 2017 situation, the World Health Organization released a report in 2014 with the aim of providing Available online 11 November 2017 updated information on this critical scenario. Among the most worrying microorganisms, Associate Editor: Luis Henrique species from the genus Candida have exhibited a high rate of resistance to antifungal drugs. Guimarães Therefore, the objective of this review is to show that the use of natural products (extracts or isolated biomolecules), along with conventional antifungal therapy, can be a very promising Keywords: strategy to overcome microbial multiresistance. Some promising alternatives are essential Candida oils of Melaleuca alternifolia (mainly composed of terpinen-4-ol, a type of monoterpene), lacto- Lactoferrin ferrin (a peptide isolated from milk) and chitosan (a copolymer from chitin).
    [Show full text]
  • Oral Antifungals Month/Year of Review: July 2015 Date of Last
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluation: Oral Antifungals Month/Year of Review: July 2015 Date of Last Review: March 2013 New Drug: isavuconazole (a.k.a. isavunconazonium sulfate) Brand Name (Manufacturer): Cresemba™ (Astellas Pharma US, Inc.) Current Status of PDL Class: See Appendix 1. Dossier Received: Yes1 Research Questions: Is there any new evidence of effectiveness or safety for oral antifungals since the last review that would change current PDL or prior authorization recommendations? Is there evidence of superior clinical cure rates or morbidity rates for invasive aspergillosis and invasive mucormycosis for isavuconazole over currently available oral antifungals? Is there evidence of superior safety or tolerability of isavuconazole over currently available oral antifungals? • Is there evidence of superior effectiveness or safety of isavuconazole for invasive aspergillosis and invasive mucormycosis in specific subpopulations? Conclusions: There is low level evidence that griseofulvin has lower mycological cure rates and higher relapse rates than terbinafine and itraconazole for adult 1 onychomycosis.2 There is high level evidence that terbinafine has more complete cure rates than itraconazole (55% vs. 26%) for adult onychomycosis caused by dermatophyte with similar discontinuation rates for both drugs.2 There is low
    [Show full text]
  • The Epidemiology and Clinical Features of Balamuthia Mandrillaris Disease in the United States, 1974 – 2016
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 August 28. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1815–1822. doi:10.1093/cid/ciy813. The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974 – 2016 Jennifer R. Cope1, Janet Landa1,2, Hannah Nethercut1,3, Sarah A. Collier1, Carol Glaser4, Melanie Moser5, Raghuveer Puttagunta1, Jonathan S. Yoder1, Ibne K. Ali1, Sharon L. Roy6 1Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 2James A. Ferguson Emerging Infectious Diseases Fellowship Program, Baltimore, MD, USA 3Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA 4Kaiser Permanente, San Francisco, CA, USA 5Office of Financial Resources, Centers for Disease Control and Prevention Atlanta, GA, USA 6Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA Abstract Background—Balamuthia mandrillaris is a free-living ameba that causes rare, nearly always fatal disease in humans and animals worldwide. B. mandrillaris has been isolated from soil, dust, and water. Initial entry of Balamuthia into the body is likely via the skin or lungs. To date, only individual case reports and small case series have been published. Methods—The Centers for Disease Control and Prevention (CDC) maintains a free-living ameba (FLA) registry and laboratory. To be entered into the registry, a Balamuthia case must be laboratory-confirmed.
    [Show full text]
  • Idweek 2013 Miltefosine Poster Final.Pdf
    Increased Patient Survival: Miltefosine for Treatment of Free-living Ameba Infections Caused by Acanthamoeba, Balamuthia, and Naegleria Jennifer R. Cope, Sharon L. Roy, Jonathan S. Yoder, Michael J. Beach BACKGROUND RESULTS CONCLUSIONS Granulomatous amebic encephalitis (GAE) Acanthamoeba Balamuthia mandrillaris Survival in Patients Who Received Miltefosine vs. Patients Who Did Not Receive Miltefosine . Number of Acanthamoeba, Balamuthia, and Naegleria infections . Subacute to chronic central nervous system infection treated with a miltefosine-containing regimen is small. Caused by the free-living amebae (FLA) Balamuthia mandrillaris and N Received Did Not Receive P- . Miltefosine-containing treatment regimen does offer a Acanthamoeba spp. Miltefosine* Miltefosine value significant survival advantage for these often fatal infections. Often fatal . CDC should provide drug to clinicians for FLA infections under an Symptoms of GAE Survived/Total (%) Survived/Total (%) expanded access IND until it becomes commercially available in Personality and . Photophobia . Non-keratitis the United States. behavioral changes . Seizures Acanthamoeba 63 5/7 (71) 9/56 (16) 0.005 . Depressed mental . Cranial nerve status dysfunction infections (1955–2012) . Fever . Visual Loss Balamuthia infections Photomicrographs of Acanthamoeba and Balamuthia (1974–2012) 60 6/14 (43) 6/46 (13) 0.05 Brain imaging trophozoites . Single or multiple ring-enhancing lesions Naegleria fowleri Naegleria infections 2/4 (50) 1/65 (1.5) 0.02 CDC’s Free-living Ameba Program Activities Magnetic resonance imaging (MRI) of patient with Balamuthia GAE (1962–2013) 69 . Providing 24/7 diagnostic services and clinical guidance to health professionals, including provision of miltefosine when indicated Primary amebic meningoencephalitis (PAM) * Miltefosine is given in combination with other antibiotics and antifungals such as: .
    [Show full text]
  • Evaluation of the Drug Treatment and Persistence of Onychomycosis
    Review TheScientificWorldJOURNAL (2004) 4, 760–777 ISSN 1537-744X; DOI 10.1100/tsw.2004.134 Evaluation of the Drug Treatment and Persistence of Onychomycosis Andrew W. Campbell1, Ebere C. Anyanwu2,*, and Mohammed Morad3 1Medical Center for Immune and Toxic Disorders, 20510 Oakhurst Drive, Suite 200, Spring TX; 2Neurosciences Research, Cahers Inc., 8787 Shenandoah Park Drive, Suite 122, Conroe, Houston, 77385 TX; 3Clalit Health Services and Division of Community Health, Department of Family Medicine, Ben Gurion University, Beer-Sheva, Israel E-mail: [email protected] Received August 1, 2004; Revised August 18, 2004; Accepted August 19, 2004; Published August 31, 2004 Onychomycosis is a common nail disease responsible for approximately 50% of diseases of the nail. It occurs more in the elderly, though several cases have been reported among children. Several factors influence, such as climate, geography, and migration. The two dermatophytes most commonly implicated in onychomycosis are Trichophyton rubrum and T. mentagrophytes, accounting for more than 90% of onychomycoses. Nonetheless, several other toxigenic molds have been implicated. For convenience, onychomycosis is divided into four major clinical presentations: distal subungal, which is the most common form of the disease; proximal subungal, which is the most common form found in patients with human immunodeficiency virus infection; superficial; and total dystrophic onychomycosis. Epidemiology of onychomycosis in adults and children is evaluated and the most common clinical symptoms addressed. Although the risk factors are discussed, the multifactorial nature of onychomycosis makes this inexhaustible. The diagnosis and treatments are difficult and the choice of appropriate antifungal drugs complex and require the knowledge of the chemical structures of the metabolites of the molds that cause onychomycosis and their interaction with the antifungal drugs.
    [Show full text]
  • ANCOBON® (Flucytosine) Capsules Rx Only
    ANCOBON® (flucytosine) capsules Rx only WARNING Use with extreme caution in patients with impaired renal function. Close monitoring of hematologic, renal and hepatic status of all patients is essential. These instructions should be thoroughly reviewed before administration of ANCOBON. DESCRIPTION ANCOBON (flucytosine), an antifungal agent, is available as 250 mg and 500 mg capsules for oral administration. In addition to the active ingredient of flucytosine, each capsule contains corn starch, lactose and talc. The 250 mg capsule shell contains black iron oxide, D&C Yellow No. 10, FD&C Blue No. 1, FD&C Yellow No. 6, gelatin and titanium dioxide. The 500 mg capsule shell contains black iron oxide, gelatin and titanium dioxide. Chemically, flucytosine is 5-fluorocytosine, a fluorinated pyrimidine which is related to fluorouracil and floxuridine. It is a white to off-white crystalline powder with a molecular weight of 129.09 and the following structural formula: CLINICAL PHARMACOLOGY Flucytosine is rapidly and virtually completely absorbed following oral administration. ANCOBON is not metabolized significantly when given orally to man. Bioavailability estimated by comparing the area under the curve of serum concentrations after oral and intravenous administration showed 78% to 89% absorption of the oral dose. Peak serum concentrations of 30 to 40 mcg/mL were reached within 2 hours of administration of a 2 g oral dose to normal subjects. Other studies revealed mean serum concentrations of approximately 70 to 80 mcg/mL 1 to 2 hours after a dose in patients with normal renal function receiving a 6-week regimen of flucytosine (150 mg/kg/day given in divided doses every 6 hours) in combination with amphotericin B.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm)
    Editorial | Journal of Gandaki Medical College-Nepal Fungal Infections (Mycoses): Dermatophytoses (Tinea, Ringworm) Reddy KR Professor & Head Microbiology Department Gandaki Medical College & Teaching Hospital, Pokhara, Nepal Medical Mycology, a study of fungal epidemiology, ecology, pathogenesis, diagnosis, prevention and treatment in human beings, is a newly recognized discipline of biomedical sciences, advancing rapidly. Earlier, the fungi were believed to be mere contaminants, commensals or nonpathogenic agents but now these are commonly recognized as medically relevant organisms causing potentially fatal diseases. The discipline of medical mycology attained recognition as an independent medical speciality in the world sciences in 1910 when French dermatologist Journal of Raymond Jacques Adrien Sabouraud (1864 - 1936) published his seminal treatise Les Teignes. This monumental work was a comprehensive account of most of then GANDAKI known dermatophytes, which is still being referred by the mycologists. Thus he MEDICAL referred as the “Father of Medical Mycology”. COLLEGE- has laid down the foundation of the field of Medical Mycology. He has been aptly There are significant developments in treatment modalities of fungal infections NEPAL antifungal agent available. Nystatin was discovered in 1951 and subsequently and we have achieved new prospects. However, till 1950s there was no specific (J-GMC-N) amphotericin B was introduced in 1957 and was sanctioned for treatment of human beings. In the 1970s, the field was dominated by the azole derivatives. J-GMC-N | Volume 10 | Issue 01 developed to treat fungal infections. By the end of the 20th century, the fungi have Now this is the most active field of interest, where potential drugs are being January-June 2017 been reported to be developing drug resistance, especially among yeasts.
    [Show full text]
  • Nails: Tales, Fails and What Prevails in Treating Onychomycosis
    J. Hibler, D.O. OhioHealth - O’Bleness Memorial Hospital, Athens, Ohio AOCD Annual Conference Orlando, Florida 10.18.15 A) Onychodystrophy B) Onychogryphosis C)“Question Onychomycosis dogma” – Michael Conroy, MD D) All the above E) None of the above Nail development begins at 8-10 weeks EGA Complete by 5th month Keratinization ~11 weeks No granular layer Nail plate growth: Fingernails 3 mm/month, toenails 1 mm/month Faster in summer or winter? Summer! Index finger or 5th digit nail grows faster? Index finger! Faster growth to middle or lateral edge of each nail? Lateral! Elkonyxis Mee’s lines Aka leukonychia striata Arsenic poisoning Trauma Medications Illness Psoriasis flare Muerhrcke’s bands Hypoalbuminemia Chemotherapy Half & half nails Aka Lindsay’s nails Chronic renal disease Terry’s nails Liver failure, Cirrhosis Malnutrition Diabetes Cardiovascular disease True or False: Onychomycosis = Tinea Unguium? FALSE. Onychomycosis: A fungal disease of the nails (all causes) Dermatophytes, yeasts, molds Tinea unguium: A fungal disease of nail caused by dermatophyte fungi Onychodystrophy ≠ onychomycosis Accounts for up to 50% of all nail disorders Prevalence; 14-28% of > 60 year-olds Variety of subtypes; know them! Sequelae What is the most common cause of onychomycosis? A) Epidermophyton floccosum B) Microsporum spp C) Trichophyton mentagrophytes D) Trichophyton rubrum -Account for ~90% of infections Dermatophytes Trichophyton rubrum Trichophyton mentagrophytes Trichophyton tonsurans, Microsporum canis, Epidermophyton floccosum Nondermatophyte molds Acremonium spp, Fusarium spp Scopulariopsis spp, Sytalidium spp, Aspergillus spp Yeast Candida parapsilosis Candida albicans Candida spp Distal/lateral subungal Proximal subungual onychomycosis onychomycosis (DLSO) (PSO) Most common; T. rubrum Often in immunosuppressed patients T.
    [Show full text]